(Q38438814)

3 September 2017

1 reference

title

Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry (English)

1 reference

3 September 2017

1 reference

Brent L Wood

1

1 reference

3 September 2017

publication date

23 April 2015

1 reference

Cytometry Part B: Clinical Cytometry

3 September 2017

published in

1 reference

3 September 2017

volume

90

1 reference

3 September 2017

issue

1

1 reference

3 September 2017

page(s)

47-53

1 reference

describes a project that uses

3 September 2017

1 reference

Flow cytometric immunophenotyping for hematologic neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Detection of minimal residual disease in acute leukemia by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Flow cytometric monitoring of residual disease in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Monitoring of minimal residual disease in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

inferred from DOI database lookup

7 January 2021

based on heuristic

Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

inferred from DOI database lookup

7 January 2021

based on heuristic

Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21239

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CYTO.B.21239

1 reference

3 September 2017

1 reference